Related Experiment Videos
Sex as a predictor of response to cancer immunotherapy - Authors' reply
Fabio Conforti1, Laura Pala1, Vincenzo Bagnardi2
1Division of Medical Oncology for Melanoma & Sarcoma, European Institute of Oncology, Milan 20141, Italy.
The Lancet. Oncology
|August 14, 2018
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
European journal of cancer (Oxford, England : 1990)·2026
Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"
European journal of cancer (Oxford, England : 1990)·2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026